SCHEMBL20138372

SCHEMBL20138372

CCCN1C(=O)C(=NC(=O)N(C)C)c2cc(Cl)ccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.52
CA1 P00915 5/20 0.52
CA2 P00918 5/20 0.52
CA9 Q16790 5/20 0.52
KDR P35968 1/20 0.52
UCHL3 P15374 2/20 0.45
UCHL1 P09936 2/20 0.45
ALDH1A1 P00352 3/20 0.40
ALDH2 P05091 2/20 0.40
ALDH3A1 P30838 2/20 0.40
ACE P12821 1/20 0.39
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRA6 Q16445 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20138371 1.00 CA12 (0.52) CA12CA1CA2CA9KDR
SCHEMBL20138381 0.87 PDE5A (0.43) CA12CA1CA2CA9KDR
SCHEMBL18189123 0.87 PDE5A (0.43) CA12CA1CA2CA9KDR
SCHEMBL20138357 0.84 CA1 (0.50) CA12CA1CA2CA9KDR
SCHEMBL20138356 0.84 CA1 (0.50) CA12CA1CA2CA9KDR
SCHEMBL18189117 0.83 ACE (0.51) CA12CA1CA2CA9ALDH1A1
SCHEMBL20138374 0.83 ACE (0.51) CA12CA1CA2CA9ALDH1A1
SCHEMBL18200160 0.82 CA1 (0.51) CA12CA1CA2CA9KDR
SCHEMBL18189066 0.82 CA1 (0.51) CA12CA1CA2CA9KDR
SCHEMBL20138331 0.82 CA1 (0.51) CA12CA1CA2CA9KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288933-B1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUND FOR RES DEV (US) 2021-10-06 EP disclosed
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2019-08-06 US disclosed
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof PARK7, OPRK1, COMT CA12 4149/4885CA1 4003/4885CA2 4610/4885
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PARK7, OPRK1, COMT CA12 4149/4885CA1 4003/4885CA2 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.